BIOGRAPHY: Steven M. Rowe was born in Baton Rouge, LA in May 1972. He received his BA degree from University of Virginia in 1994, an MD from Vanderbilt University in 1998 and a MSPH from the University of Alabama at Birmingham in 2005. He completed a combined Internal Medicine and Pediatrics internship and residency at the University of Alabama at Birmingham. He also completed a combined Pulmonary and Critical Care Medicine and Pediatric Pulmonary fellowship at the University of Alabama at Birmingham. In 2005, Dr. Rowe was appointed to the position of Instructor in the Division of Pulmonary, Allergy and Critical Care Medicine, Pediatric Pulmonology, and Physiology & Biophysics at the University of Alabama at Birmingham. He was promoted to Assistant Professor in 2006. Dr. Rowe's research affiliations are with the Cystic Fibrosis Research Center and Center for Biophysical Sciences and Engineering. Dr. Rowe was promoted to Professor in 2014 and in 2015 was appointed as Director of the UAB Cystic Fibrosis Research Center. He also serves as Director of the CFF Therapeutics Development Network, Center for CFTR Detection. Dr. Rowe is board certified in Internal Medicine, Pediatrics, Pulmonary Medicine and Critical Care Medicine. CLINICAL INTERESTS: Dr. Rowe specializes in developing new treatments for cystic fibrosis, the most common autosomal recessive genetic disease, and the cause of severe pulmonary disease affecting children and young adults. He maintains expertise in the design and conduct of clinical trials targeting the basic CF defect. Dr. Rowe also has an interest in Biomarkers of CF, including ion transport and the relation between mucus stasis and inflammation. Dr. Rowe founded the CF Transition Clinic, a collaborative project between the adult and pediatric CF care centers. ACADEMIC AND RESEARCH INTERESTS: In concert with his clinical and clinical research interests, Dr. Rowe maintains a research laboratory specializing in the mechanisms underlying cystic fibrosis, including agents intended to rescue the basic CF defect. These studies routinely utilize cultured cells, human tissues, and novel animal models. Dr. Rowe directs UAB Cystic Fibrosis Research Center and the Center for CFTR Detection, a National Resource Center of the CF Therapeutics Development Network, responsible for development, interpretation, and quality assurance of in vivo assays of CFTR function. Dr. Rowe is funded by the National Institutes of Health, the Cystic Fibrosis Foundation, and industry collaborators for these efforts. He also co-directs the CFF funded Mucus Clearance Consortium, including basic and translational scientists charged with improving the mechanistic understanding of the mucus clearance defect in cystic fibrosis, and novel means to monitor the process. He co-invented micro-Optical coherence tomography imaging to monitor mucus clearance, and helped co-develop a new rat model to test new interventions.